Company Overview and News


Add FRX
to your dashboard

Headline News

Fennec Provides Corporate Update and Announces Second Quarter 2017 Results

2017-08-11 marketwired
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Aug. 11, 2017) - Fennec Pharmaceuticals Inc. (TSX:FRX) (OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the second quarter ended June 30, 2017. (0-1)

Fennec Announces Results of Annual Meeting

2017-06-28 marketwired
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - June 28, 2017) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) today announced that the nominees listed in the management proxy circular dated May 19, 2017 (the "Circular") for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on June 27, 2017.

Fennec Announces $7.6 Million Private Placement of Common Shares Led by venBio Select Advisor

2017-06-08 marketwired
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - June 8, 2017) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) (the "Company" or "Fennec"), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today that it has completed a non-brokered private placement (the "Offering") of 1,900,000 common shares for gross proceeds of US$7,600,000.

Fennec Announces Launch of European Named Patient Programme for Sodium Thiosulfate for Pediatric Patients With Standard Risk Hepatoblastoma

2017-05-30 marketwired
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - May 30, 2017) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced the launch of a Named Patient Programme (NPP) in Europe for STS. Fennec's NPP is intended to make STS available to patients before commercial availability in certain countries.

Fennec Provides Corporate Update and Announces First Quarter 2017 Results

2017-05-12 marketwired
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - May 12, 2017) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the first quarter ended March 31, 2017.

Fennec to Present at Pioneers 2017 Joseph Gunnar Conference on May 2, 2017 in New York City

2017-04-27 marketwired
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - April 27, 2017) - Fennec Pharmaceuticals, Inc. (TSX:FRX)(OTCQB:FENCF), today announced that Rosty Raykov, CEO of Fennec, will be presenting at the PIONEERS 2017 Joseph Gunnar Conference on Tuesday, May 2 at 2:00 PM ET in the South Salon II at the Mandarin Oriental Hotel in New York City. Management will also be available to meet with investors during the conference.

Fennec to Present at 19th Annual BIO CEO & Investor Conference

2017-02-09 marketwired
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Feb. 9, 2017) - Fennec Pharmaceuticals, Inc. (TSX:FRX)(OTCQB:FENCF), today announced that Rosty Raykov, CEO of Fennec, will present at the 19th BIO CEO & Investor Conference on Monday, February 13, 2017 at 1:30 PM ET at the Waldorf Astoria Hotel in New York City.

Fennec Announces the Lancet Oncology Publication of Children's Oncology Group Study of Sodium Thiosulfate

2016-12-01 marketwired
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Dec. 1, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX) (OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced The Lancet Oncology published the results from the Children's Oncology Group, "Effects of Sodium Thiosulfate versus Observation on Development of Cisplatin-Induced Hearing Loss and Survival in Children with Cancer: Results from the Children's Oncology Group ACCL0431 Randomised Cohort Trial".

Fennec Announces Repricing of Warrants

2016-11-15 marketwired
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Nov. 15, 2016) - Fennec Pharmaceuticals Inc. (the "Company" or "Fennec") (TSX:FRX)(OTCQB:FENCF) announced today that its board of directors has approved an amendment to the exercise price of the outstanding 366,133 common share purchase warrants originally issued on December 3, 2014 from USD$3.60 to USD$2.50 (the "Amendment"). No other changes will be made to the terms of the Warrants, and the Warrants expire on December 3, 2016.

Fennec Provides Corporate Update and Announces Third Quarter 2016 Results

2016-11-14 marketwired
SIOPEL 6 Updated Interim Results Presented at the International Society of Pediatric Oncology (SIOP) - confirms no evidence of tumor protection and final audiometry results will be available in the fourth quarter of 2017

Fennec Announces Update of SIOPEL 6 Study on Sodium Thiosulfate (STS) Presented at the International Society of Paediatric Oncology (SIOP) 2016 Meeting

2016-10-24 marketwired
- No difference in Event free Survival (EFS) and Overall Survival (OS) at 2 years for cisplatin alone vs cisplatin + STS with no evidence of tumor protection

Fennec to Present at Rodman & Renshaw 18th Annual Global Investment Conference in New York on September 13, 2016

2016-09-08 marketwired
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Sept. 8, 2016) - Fennec Pharmaceuticals, Inc. (TSX:FRX)(OTCQB:FENCF) today announced that Rosty Raykov, CEO of Fennec, will present at the Rodman & Renshaw 18th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The Company will be presenting at 3:25 EDT on Tuesday, September 13, 2016. The conference is being held at the Lotte New York Palace Hotel in New York City.

Fennec Provides Corporate Update and Announces Second Quarter 2016 Results

2016-08-12 marketwired
Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the second quarter ended June 30, 2016.

Fennec Announces Appointment of Marco Brughera to the Board of Directors

2016-08-11 marketwired
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Aug. 11, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, announced today the appointment of Marco Brughera, DVM, CEO and Global Head of Sigma Tau Rare Disease, to its Board of Directors.

Fennec to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference in New York on July 13, 2016

2016-07-06 marketwired
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - July 6, 2016) - Fennec Pharmaceuticals, Inc. (TSX:FRX) (OTCQB:FENCF), today announced that the Company will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference in New York City at 10:45 AM EDT on Wednesday, July 13, 2016. The conference is being held at the Le Parker Meridian in New York City.